Aptevo lines up $3M from warrant exercises — its second raise in three months
What's the deal? Aptevo TherapeuticsDealroom has a profile for this one. Try Dealroom →, a Seattle-based clinical-stage biotech, said certain warrant holders have agreed to exercise existing warrants for about $3 million in gross proceeds. The holders will buy up to 2,777,778 shares at a reduced $1.08 exercise price, with the transaction expected to close on or about November 12, 2026.
What's the catch? In return, Aptevo will issue new warrants covering up to 13,888,890 more shares at the same $1.08 price. If exercised, those warrants create substantial dilution — making this near-term cash come at a meaningful equity cost.
Why now? This is Aptevo's second warrant-linked raise in roughly three months. In August it raised about $4.5 million through warrant exercises and a PIPE, and it reported $9.8 million in cash at June 30.
What's the endgame? Aptevo develops bispecific and trispecific immunotherapies for cancer. Its lead candidate, mipletamig, is in a Phase 1b/2 trial for frontline acute myeloid leukemia and is advancing toward Phase 2 planning.
The company intends to use net proceeds for working capital. Roth Capital PartnersDealroom has a profile for this one. Try Dealroom → is acting as financial advisor; the new warrants were offered in a private placement.
The signal: Back-to-back dilutive raises underscore how clinical-stage biotechs lean on repeated equity financing to fund operations while chasing milestones. For Aptevo, the $3 million buys runway — at the expense of shareholders if the new warrants convert.
Read more: finance.yahoo.com
Image credit: Generated with Gemini
